C-QXFTTisento Therapeutics
sGC stimulation, mitochondrial disease
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QXFT
C-QXFTC-QXFTsGC stimulation, mitochondrial disease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Tisento Therapeutics sGC stimulation, mitochondrial disease
Tisento Therapeutics is focused on developing zagociguat as a treatment for MELAS, a debilitating mitochondrial disease with no effective treatments. Zagociguat is described as an oral, once-daily, first-in-class, brain-penetrant soluble guanylate cyclase stimulator. The company says it incorporates input from people living with serious diseases, families, clinicians, regulatory agencies, and scientific data into its research and trial design.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Tisento Therapeutics — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic